Arginase impairs hypoxic pulmonary vasoconstriction in murine endotoxemia by Petersen, Bodil et al.
RESEARCH Open Access
Arginase impairs hypoxic pulmonary
vasoconstriction in murine endotoxemia
Bodil Petersen1,2†, Cornelius J. Busch1,3*† , Grigorij Schleifer1, Dominik Schaack3, Felix Lasitschka4,
Kenneth D. Bloch1, Donald B. Bloch1,5 and Fumito Ichinose1*
Abstract
Background: Hypoxic pulmonary vasoconstriction (HPV) optimizes the match between ventilation and perfusion in
the lung by reducing blood flow to poorly ventilated regions. Sepsis and endotoxemia impair HPV. We previously
showed that nitric oxide synthase 2 (NOS2) is required, but not sufficient, for the effect of endotoxin on HPV. The
aim of the current study was to identify additional factors that might contribute to the impairment of HPV during
endotoxemia.
Methods: Gene expression profiling was determined using pulmonary tissues from NOS2-deficient (NOS2−/−) and
wild-type mice subjected to endotoxin or saline challenge (control). HPV was accessed as the percentage increase
in left pulmonary vascular resistance (LPVR) in response to left main bronchus occlusion (LMBO) in wild-type mice.
Results: Among the 22,690 genes analyzed, endotoxin induced a greater than three-fold increase in 59 and 154
genes in the lungs of wild-type and NOS2−/− mice, respectively. Of all the genes induced by endotoxin in wild-type
mice, arginase 1 (Arg1) showed the greatest increase (16.3-fold compared to saline treated wild-type mice). In
contrast, endotoxin did not increase expression of Arg1 in NOS2−/− mice. There was no difference in the endotoxin-
induced expression of Arg2 between wild-type and NOS2-deficient mice. We investigated the role of arginase in
HPV by treating the mice with normal saline or the arginase inhibitor Nω-hydroxy-nor-L-arginine (norNOHA). In
control mice (in the absence of endotoxin) treated with normal saline, HPV was intact as determined by
profound LMBO-induced increase in LPVR (121 ± 22% from baseline). During endotoxemia and treatment with
normal saline, HPV was impaired compared to normal saline treated control mice (33 ± 9% vs. 121 ± 22%,
P < 0.05). HPV was restored in endotoxin-exposed mice after treatment with the arginase inhibitor norNOHA
as shown by the comparison to endotoxemic mice treated with normal saline (113 ± 29% vs, 33 ± 9%, P < 0.
05) and to control mice treated with normal saline (113 ± 29% vs, 121 ± 22%, P = 0.97).
Conclusions: The results of this study suggest that endotoxemia induces Arg1 and that arginase contributes
to the endotoxin-induced impairment of HPV in mice.
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Background
Hypoxic pulmonary vasoconstriction (HPV) diverts
blood flow away from poorly- to better-ventilated re-
gions of the lung, thereby optimizing gas exchange. The
sensor and effector mechanisms responsible for HPV are
intrinsic to pulmonary arterial smooth muscle cells [1].
Although it has been shown that HPV is modulated by a
number of vasoactive mediators including nitric oxide
(NO) and arachidonic acid metabolites, the precise
mechanisms that mediate HPV remain incompletely
understood [1–5].
HPV is impaired in patients with sepsis and in animal
models of endotoxemia [2–7]. Impaired HPV (i.e., re-
duced pulmonary vasoconstrictor response in hypoxic
lung regions) contributes to systemic hypoxemia during
sepsis or endotoxemia. NO is produced by NO synthases
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(NOS1, NOS2, and NOS3). While NOS3 is constitutively
expressed in vascular endothelial cells and importantly
regulates pulmonary vascular tone, NOS2 is induced by
inflammatory stimuli such as endotoxin. In a previous
study, we showed that endotoxin impairs HPV in
wild-type mice but not in mice with congenital NOS2
deficiency (NOS2−/−) leading to lower arterial oxygen
tensions in wild-type mice than in NOS2−/− mice after
endotoxin challenge. In saline-treated wild-type and
NOS2−/− mice, the inhalation of 40 ppm NO for 22 h did
not affect HPV, suggesting that a high level of NO, by it-
self, is not sufficient to impair HPV. When endotoxemic
wild-type and NOS2−/− mice inhaled 40 ppm NO for 22
h, HPV was impaired to the same degree in both geno-
types [2]. The results of these studies show that NO and
at least one additional endotoxin-induced factor are re-
quired for endotoxin to impair HPV.
In the current study, we hypothesized that one or
more gene(s) are differentially expressed in the lungs of
wild-type and NOS2−/− mice after endotoxin challenge.
We used an unbiased transcriptional array approach to
identify genes that may have increased or decreased ex-
pression after endotoxin exposure in wild-type mice, but
not NOS2−/− mice. Here, we report that expression of
arginase 1 (Arg1) was markedly increased in the lungs of
wild-type mice after endotoxin challenge. Endotoxin
marginally decreased the expression of Arg1 in NOS2−/−
mice. The arginase inhibitor Nω-hydroxy-nor-L-arginine
restored HPV in wild-type mice. These observations
identify a critical role for arginase in endotoxin-induced
impairment of HPV.
Materials and methods
Animals and experimental setting
Male NOS2−/− mice and their wild-type controls
(C57BL/6 J) were purchased from The Jackson Labora-
tory (Bar Harbor, Maine). The body weight ranged
between 21 and 27 g. Mice were challenged with intra-
venous administration of either normal saline (0.1 ml/10
g body weight) or lipopolysaccharide (LPS, Escherichia
coli O111:B4, Sigma, St Louis, MO; 20mg/kg, dissolved
in normal saline 0.1 ml/10 g body weight).
Microarray analysis
For microarray analysis, lungs were harvested from
wild-type mice 22 h after challenge with either saline (N =
4) or LPS (N = 3) or from NOS2−/− mice 22 h after saline
(N = 1) or LPS (N = 3) challenge. RNA, cDNA, and labeled
cRNA were generated as previously described [8]. Frag-
mented cRNA was hybridized to Affymetrix mouse gen-
ome MOE430A Array containing 22,690 gene entries with
the GeneChip Fluidics Station 450 and scanned with the
GeneChip® Scanner 3000. Affymetrix GeneChip 5.0 soft-
ware was used for data analysis according to Affymetrix
protocols. Microarray data processing was performed in
the R environment. Bioconductor package “affy” was used
for data input, background correction, normalization and
calculation of expression values. Data sets were annotated
with official gene symbols originating from package
“moe430a.db” using “annotate”. Resulting gene sets were
annotated using in-house scripts and technical informa-
tion from Affymetrix.
Measurement of gene expression
To confirm the increase in pulmonary Arg1 expression
found in the microarray analysis of endotoxemic
wild-type mice, but not NOS2−/− mice, additional
wild-type and NOS2−/− mice received either normal sa-
line or LPS (N = 6 for each of the four groups).
Twenty-two hours later, total RNA was isolated from
homogenized lungs using Trizol (Invitrogen Life Tech-
nologies, Carlsbad, CA, USA). cDNA was generated with
MMLV reverse transcriptase (Promega, Madison, WI,
USA) and random primers (Promega, Madison, WI,
USA). Real-time qPCR was performed using the ABI
Prism 7000 Sequence Detection System (Applied Biosys-
tems, Foster City, CA, USA) using FAM MGB primers
for Arg1 and arginase 2 (Arg2, Applied Biosystems,
Foster City, CA, USA). 18S ribosomal RNA was detected
using 18S VIC MGB primers (Applied Biosystems,
Foster City, CA, USA) and Taqman Universal PCR
Master Mix (Applied Biosystems, Foster City, CA, USA).
Changes in Arg1 and Arg2 mRNA expression were de-
termined using the ΔΔCt method with normalization to
18S ribosomal RNA.
Measurement of Arg1 protein expression
Immunoblots were performed to assess levels of Arg1
and GAPDH. Lungs from wild-type and NOS2−/− mice
with and without 22 h of endotoxemia were harvested,
homogenized at 4 °C in PBS with 5 mM EGTA and
protease inhibitor mix (Roche Diagnostics GmbH,
Germany), and centrifuged at 10,000 g at 4 °C for 10
min. Protein in the supernatant protein was subjected to
electrophoresis, transferred to a PVDF membrane, and
probed with anti-Arg1 antiserum (1500, Lifespan Biosci-
ences, Seattle, WA, USA) and anti-GAPDH antiserum
(1:10,000, MerckMillipore, Darmstadt, Germany). Proteins
were visualized using a LICOR infrared imager (Odyssey
CLx) and quantitative densitometric analysis was per-
formed (Odyssey Image Studio v3.1). The amount of argi-
nase relative to GAPDH was determined.
Immunoenzyme staining
To localize Arg1 expression, lungs of wild-type mice
were fixed in paraformaldehyde 22 h after challenge with
saline (N = 5) or endotoxin (N = 5). Immunoenzyme
stainings were performed on 2 μm paraffin-embedded
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sections using standard avidin-biotin anti-alkaline phos-
phatase technique (Vector Laboratories, Burlingame,
CA) according to the manufacturer’s instructions. Tris-
buffered saline supplemented with 0.2% bovine serum al-
bumin (Biotrend, Cologne, Germany) was used as buffer.
Primary antibody dilutions of rabbit polyclonal antibody,
1/50 (H-52, Santa Cruz, Dallas, Texas) and an isotype-
and concentration-matched rabbit control Ig (Dianova,
Hamburg, Germany) were prepared in this buffer and
incubated for 1 h at room temperature. A biotinylated
donkey anti-rabbit IgG Ab, 1/100 (Jackson ImmunoRe-
search, Newmarket, UK), was used as a secondary reagent
(30min at room temperature). Naphthol AS-biphosphate
(Sigma) with New-fuchsin (Merck, Darmstadt, Germany)
was used as the substrate for alkaline phosphatase. Slides
were counterstained with hematoxylin (Sigma).
Measurement of hypoxic pulmonary vasoconstriction in mice
To investigate the effect of arginase on HPV, mice were
initially challenged with either LPS or normal saline
(control). Twenty-one hours later, mice were treated
with an intravenous bolus of the arginase inhibitor
Nω-hydroxy-nor-L-arginine (norNOHA, Cayman Chem-
ical, Ann Arbor, Michigan; 20 mg/kg or 40 mg/kg) or
normal saline. One hour later, HPV was measured as de-
scribed previously [3–5, 7]. Mice were anesthetized and
mechanically ventilated with a respiratory frequency of
100–110 breaths per minute, a tidal volume of 10 ml/kg
body weight, the peak inspiratory pressure of approxi-
mately 10 cm H2O, positive end-expiratory pressure 2
cm H2O, and at an inspired oxygen fraction of 1.0. An
arterial line was placed in the left carotid artery, and a
left-sided thoracotomy was performed. A custom-made
polyethylene catheter was positioned in the main pul-
monary artery, and a flow probe was placed around the
left pulmonary artery. Heart rate, systemic arterial pres-
sure (SAP), pulmonary arterial pressure (PAP), and left
pulmonary arterial blood flow (QLPA) were continu-
ously measured and recorded (DI 720; Dataq Instru-
ments, Akron, OH). Left lung alveolar hypoxia and
collapse was induced by left mainstem bronchus occlu-
sion (LMBO). A 50% transient occlusion of the inferior
vena cava was repeated three times before and during
LMBO to estimate left pulmonary vascular resistance
(LPVR). LPVR was calculated from the slope of the
PAP/QPLA relationship. The LMBO-induced increase in
LPVR was expressed as the percentage increase of LPVR
during LMBO from the baseline.
Measurement of arterial blood gases
After hemodynamic measurements were obtained,
blood was sampled from the left carotid artery, antic-
oagulated with heparin, and blood gas analyses were
performed using a Rapid Lab 840 (Chiron Diagnos-
tics, Medfield, MA).
Statistical analysis
Data are expressed as mean ± SD. P values less than 0.05
were considered statistically significant. Statistical ana-
lyses were performed using Sigma Stat 3.0 (Systat Soft-
ware Inc., Richmond, CA). Normality distribution of
data was checked using the Kolmogorov-Smirnov test
with Lillefors correction. For the comparison between
the groups, data were analyzed using ANOVA with a
post-hoc Tukey test for normally distributed data or
using Kruskal Wallis ANOVA on ranks with a
post-hoc Turkey test for not normally distributed data.
Hemodynamic changes before (baseline) and during
LMBO were compared with a paired t-test.
For the microarray data, the differential expression
gene set annotation was performed as follows. The data
analysis from wild-type and NOS2−/− mice after chal-
lenge with either saline or LPS was conducted with
“limma” (Linear Models for Microarray and RNA-Seq,
https://bioconductor.org) [9]. Empirical Bayes statistics
for differential expression was calculated for both geno-
types and conditions. To allow comparison of data sets
moderated F-statistics were applied. Differentially
up-regulated genes were selected that showed linear ex-
pression values of at least 3-fold after 22 h after LPS
challenge in comparison to saline challenge. Gene candi-
dates were considered as down-regulated if the respect-
ive expression values were decreased to 0.3-fold or less.
Probability values were adjusted for multiple testing
using the Benjamini–Hochberg procedure. Genes that
were either up-regulated (≥ 3.0) or down-regulated (≤ 0.3)
after treatment with LPS compared to saline were identi-
fied in NOS2−/− and wild-type mice. Then genes with
endotoxin-induced increased expression (≥ 3.0) or de-
creased expression (≤ 0.3) were compared in wild-type
and NOS2−/− mice. The Supplemental files summarize the
results as follows: Additional file 1. Genes with increased
expression in endotoxemic wild-type, but not in endo-
toxemic NOS2−/− mice; Additional file 2. Genes with
decreased expression in endotoxemic wild-type, but
not endotoxemic NOS2−/− mice; Additional file 3.
Genes with increased expression in endotoxemic
NOS2−/−, but not endotoxemic wild-type mice; Add-
itional file 4. Genes with a decreased expression endotoxe-
mic NOS2−/−, but not endotoxemic wild-type mice.
Results
Endotoxin challenge increases Arg1 levels in the lungs;
dependence on NOS2
Endotoxin impairs HPV in wild-type mice, but not in
NOS2−/− mice [2]. We hypothesized that differences in
endotoxin-induced gene expression between wild-type
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mice and NOS2−/− mice might explain the different re-
sponse to endotoxin in the two genotypes. Therefore, we
compared the transcriptional profile of lungs from
wild-type and NOS2−/− mice 22 h after endotoxin chal-
lenge using RNA microarrays and analyzed the data for
up- and down-regulated gene expression. The microar-
rays assessed the expression of 22,690 genes. Compared
to the lungs of control wild-type mice treated with sa-
line, endotoxin challenge induced a greater than
three-fold increase in 59 genes and a three-fold decrease
in 72 genes in the lungs of wild-type mice (Additional
file 1 and Additional file 2). Compared to the lungs of
NOS2−/− mice challenged with saline, LPS caused an
up-regulation of 154 genes and a down-regulation of 93
genes in the lungs of NOS2−/− mice (Additional file 3
and Additional file 4). Of the 800 genes that had
three-fold altered expression by endotoxin, 346 were
up-regulated or down-regulated in the lungs of both ge-
notypes (Fig. 1). However, the results of the microarray
analysis indicated that the effect of endotoxin on Arg1
expression was discordant in the two genotypes:
Expression of Arg1 was up-regulated 16.3-fold in the
lungs of LPS-treated wild-type mice; LPS induced a 10%
decrease in the expression of Arg1 in LPS-treated
NOS2−/− mice. In wild-type mice, LPS challenge induced
a 4.8-fold increase in Arg2 gene expression compared to
saline-treated wild-type mice. Exposure of NOS2−/− mice
to LPS caused a similar, 6.1-fold increase in Arg2 gene
expression compared to saline challenged NOS2−/− mice.
These results suggest that endotoxin up-regulates Arg1
expression in the lungs of wild-type, but not NOS2−/−
mice, while endotoxemia induces Arg2 expression to a
similar extent in both genotypes.
To verify the microarray results, pulmonary mRNA
levels of Arg1 and Arg2 were measured using qPCR. LPS
challenge increased Arg1 mRNA levels in the lungs of
wild-type mice (17.9-fold increase compared to saline-
challenged wild-type mice, P < 0.05) but not in NOS2−/−
Fig. 1 Up-regulated genes in the lungs of endotoxemic wild-type,
but not NOS2-deficient mice. Whole lung tissues from wild-type
mice treated with (N = 3), and without (N = 4), endotoxin and from
NOS2−/− mice treated with (N = 3), and without (N = 1), LPS were
studied. The grey dots show the log2 fold change in gene expression
upon LPS exposure; the x-axis represents changes in wild-type mice
and the y-axis changes in NOS2−/− mice. The transcriptional profiles
revealed a contrasting gene expression of pulmonary Arg1 in wild-type
and NOS2−/− mice after LPS challenge: Arg1 expression increased in
endotoxemic wild-type mice compared to saline challenged wild-type
mice (positive scaling on the x-axis). In contrast, Arg1 expression did
not increase in endotoxemic NOS2−/− mice compared to the saline-
treated NOS2−/− mice (negative scaling on the y-axis). Arg2 expression
increased in both strains after LPS challenge (positive scaling on the
x- and y-axis).
A
B
Fig. 2 Pulmonary mRNA expression of Arg1 and Arg2 in wild-type
mice and NOS2−/− mice. Endotoxin increased the pulmonary Arg1
mRNA expression in wild-type mice but not in NOS2−/− mice (Panel
a). The pulmonary Arg2 mRNA expression was similar in wild-type
mice and NOS2−/− mice after LPS challenge (Panel b). Tissue samples
were taken 22 h after challenge with either saline (control) or LPS.
N = 6 per group; data are presented as mean ± SD; * P < 0.05 vs.
saline-challenged wild-type mice, # P < 0.05 vs. saline-challenged
NOS2−/− mice, and § P < 0.05 vs. endotoxin-challenged NOS2−/− mice
Petersen et al. Respiratory Research          (2019) 20:109 Page 4 of 11
mice (0.67-fold decrease compared to saline challenged
wild-type mice, P = 0.07) (Fig. 2a). Endotoxin increased
Arg2 mRNA levels similarly in the lungs of wild-type
mice and NOS2−/− mice (8.8-fold increase vs 9.1-fold in-
crease, P = 0.90, Fig. 2b). Immunoblots were used to
measure the protein levels of Arg1 in the lungs of
wild-type and NOS2−/− mice after challenge with saline
or LPS. LPS challenge increased the protein level of
Arg1 in wild-type, but not in NOS2−/−, mice (Fig. 3).
Taken together, the results confirm that endotoxin chal-
lenge induces a marked increase in Arg1 expression in
the lungs. In contrast, induction of Arg2 expression is
similar in the two genotypes.
Endotoxin increased Arg1 immunoreactive protein
expression in small pulmonary arteries, bronchial
epithelium and connective tissue
To evaluate the location of Arg1 protein expression, lung
sections of wild-type mice were stained with Arg1 spe-
cific antibodies 22 h after challenge with saline (A) or
endotoxin (B) (Fig. 4). Arg1 expression was found in
walls of small pulmonary arteries, bronchial epithelium,
and in connective tissue.
An arginase inhibitor, norNOHA, restores HPV after LPS
challenge
To determine the physiological impact of arginase on
HPV, we examined the effects of the arginase inhibitor
norNOHA on HPV in anesthetized wild-type mice. At
baseline, the hemodynamic parameters did not differ be-
tween the mice in five experimental groups: 1)
saline-challenged control mice treated with normal
saline 21 h after the initial challenge; 2) control mice
treated with norNOHA 21 h after the saline challenge;
3) LPS-challenged mice treated with normal saline 21 h
after the initial challenge; 4) LPS-challenged mice
treated with 20 mg/kg norNOHA 21 h after the initial
challenge, and 5) LPS-challenged mice treated with
40 mg/kg norNOHA 21 h after the initial challenge
(Table 1).
During LMBO, the heart rates were comparable be-
tween the groups. The SAP remained stable before and
during LMBO in all groups except control mice that
were treated with norNOHA. In this group, the SAP de-
creased compared to baseline (97 ± 11 mmHg vs. 77 ± 7
mmHg, P < 0.05), suggesting that the arginase inhibitor
caused systemic vasodilation. Endotoxemic mice that re-
ceived normal saline (instead of norNOHA) had a small
but statistically significant decrease in SAP during
LMBO compared to baseline (96 ± 14mmHg vs. 93 ± 16
Fig. 3 Pulmonary expression of Arg1 in wild-type and NOS2−/− mice.
The level of Arg1 protein was low in the lungs of saline-treated wild-
type mice (N = 6) and was markedly increased in the lungs of wild-
type mice treated with LPS (N = 6). Arg1 protein level were low in
NOS2−/− mice challenged with saline (control, N = 4) or endotoxin
(N = 5). Lungs were harvested 22 h after challenge with either saline
(control) or lipopolysaccharide (LPS). Data are presented as mean ±
SD; * P < 0.05 vs. saline-challenged wild-type mice, # P < 0.05 vs.
saline-challenged NOS2−/− mice, and § P < 0.05 vs. endotoxin-
challenged NOS2−/− mice
Fig. 4 Arg1 immunostaining in lung sections of wild-type mice. Arg1
immunoreactivity in lungs of mice after saline (a) or endotoxin
challenge (b). Immunoenzyme stainings were performed on paraffin-
embedded sections using polyclonal rabbit anti-Arg1 and counterstained
with hematoxylin. Representative image shows Arg1 immunoreactive
protein (purple-brown) in bronchial epithelium (BR), connective tissue
(CT) and small pulmonary arteries (PA)
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mmHg, P < 0.05). The PAP increased compared to base-
line during LMBO in each group (Table 1).
To investigate the effect of arginase inhibition on
HPV, we measured the percentage increase in LPVR be-
fore and during LMBO. In control mice treated with
normal saline, LMBO caused a ~ 121% increase in
LPVR from baseline (Fig. 5a). In control mice treated
with norNOHA, the LPVR response to LMBO was at-
tenuated compared to control mice treated with saline
(80 ± 27% vs 121 ± 22%, P < 0.05). Mice challenged with
LPS and treated with normal saline had an impaired in-
crease in LPVR in response to LMBO compared to
control mice treated with normal saline (33 ± 9% vs.
121 ± 22%, P < 0.05). The increase in LPVR in response
to LMBO was also smaller in the LPS-challenged mice
treated with norNOHA at 20 mg/kg compared to the
control mice treated with normal saline (46 ± 28% vs.
121 ± 22%, P < 0.05). In contrast, treatment with nor-
NOHA at 40 mg/kg restored the increase in LPVR in
response to LMBO in LPS-challenged mice to a level
that was comparable to that of control mice treated
with normal saline (113 ± 29% vs 121 ± 22%, P = 0.97,
Fig. 5a). These results show that the arginase inhibitor
norNOHA, at a dosage of 40 mg/kg but not 20 mg/kg,
restores HPV when administered to mice 22 h after
endotoxin challenge.
Restoration of HPV in endotoxemic mice improves systemic
arterial oxygen tensions during LMBO
To estimate the impact of HPV on intrapulmonary
shunt and systemic oxygenation, arterial blood gas ten-
sions were measured during LMBO at the end of the
HPV measurements (Fig. 5a, Table 2). The arterial pH of
endotoxemic mice treated with normal saline, 20 or 40
mg/kg of norHOHA was lower than the arterial pH of
control mice treated with normal saline (P < 0.05 for all
three comparisons) or control mice treated with 40mg/
kg norNOHA (P < 0.05 for all three comparisons). Ac-
cordingly, the arterial base excess of endotoxemic mice
after treatment with normal saline, 20 or 40 mg/kg nor-
NOHA was smaller than the arterial base excess of con-
trol mice that received normal saline (P < 0.05 for all
three comparisons) or control mice treated with 40mg/
kg norNOHA (P < 0.05 for all three comparisons). There
was no difference in the arterial carbon dioxide tension
between all experimental groups, suggesting that endo-
toxin induced a metabolic acidosis. The hemoglobin
concentrations were similar in all mice. The arterial oxy-
gen tension (PaO2) was highest in control mice treated
with normal saline during LMBO. There was a small but
significant decrease in PaO2 in control mice treated with
norNOHA compared to normal saline (200 ± 38 mmHg
vs. 267 ± 38 mmHg, P < 0.05). During LMBO, the PaO2
Table 1 Hemodynamic measurements
Control LPS
NS norNOHA
(40mg/kg)
NS norNOHA
(20mg/kg)
norNOHA
(40mg/kg)
HR
(bpm)
Baseline 593±50 619±57 605±61 651±54 631±62
LMBO 584±44 626±71 603±50 634±74 636±68
SAP
(mmHg)
Baseline 93±18 97±11 96±14 95±7 102±4
LMBO 91±12 77±7A* 93±16* 92±9 101±6
PAP
(mmHg)
Baseline 17±2 17±1 18±2 16±2 17±1
LMBO 19±1* 19±1* 20±1* 19±4* 20±2*
QLPA
(ml/min)
Baseline 2.3±0.3 2.6±0.5 2.8±0.4 2.9±0.9 2.4±0.3
LMBO 1.4±0.2* 1.9±0.5* 2.3±0.4B* 2.6±1.0AB 1.6±0.3*
Hemodynamic parameters before (baseline) and during left mainstem bronchus occlusion (LMBO) in wild-type mice 22 h after challenge with saline (control) or
endotoxin (LPS). One hour prior to the measurement, mice were treated with normal saline (NS) or with the arginase inhibitor Nω-hydroxy-nor-Arginine
(norNOHA). N = 7 per group
HR heart rate, SAP systemic arterial pressure, PAP pulmonary arterial pressure, QLPA flow rate in the left pulmonary artery, bpm beats per minute, mmHg
millimeters of mercury, and ml/min milliliter per minute
Data are presented as mean ± SD. A P < 0.05 vs. LPS norNOHA 40 mg/kg, B P < 0.05 vs. control NS, * P < 0.05 vs. baseline
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was lower in LPS-challenged mice treated with normal
saline or 20 mg/kg norNOHA compared to control mice
treated with normal saline (P < 0.05 for each compari-
son). In contrast, treatment of endotoxemic mice with
40mg/kg norNOHA restored the PaO2 to levels that
were comparable to those in control mice (not chal-
lenged with LPS) treated with saline (not treated with
norNOHA) (234 ± 25mmHg vs. 267 ± 38 mmHg, P =
0.35). These results suggest that treatment with 40mg/
kg norNOHA restores HPV and decreases
intrapulmonary shunt in endotoxemic mice with an im-
provement in systemic arterial oxygenation.
Discussion
The current study used expression microarrays to iden-
tify one or more genes that might contribute, together
with NO, to the endotoxin-induced impairment of HPV.
Transcriptional profiling revealed that Arg1 was the
most up-regulated gene in the lungs of wild-type mice
after endotoxin challenge and that Arg1 was marginally
decreased in endotoxemic NOS2−/− mice. The endotoxin-
induced increase in Arg1 mRNA in wild-type, but not in
NOS2−/− mice was confirmed using qPCR. Immunoblots
showed that the differences in Arg1 mRNA levels resulted
in corresponding differences in Arg1 protein levels. Im-
munohistochemical analysis revealed that endotoxin in-
duced Arg1 expression in the walls of small pulmonary
artery, bronchial epithelium, and connective tissues in
wild-type mice. The functional importance of arginase in
the endotoxin-induced impairment of HPV was supported
by the restoration of HPV by the arginase inhibitor nor-
NOHA. Taken together, these results reveal a critical role
for arginase in the impairment of HPV during endotoxe-
mia in mice.
The production of NO by NOS depends on the avail-
ability of L-arginine because no other amino acid or
guanidino-containing compound can substitute as a sub-
strate for NOS. L-arginine is metabolized by NOS to
NO and L-citrulline and by arginase to urea and
L-ornithine (Fig. 6a) [10]. Because L-arginine is the sub-
strate for both NOS and arginase, one might expect that
inhibition of arginase would increase the availability of
L-arginine for NOS to produce more NO and thereby
impair HPV. In this study, the pulmonary level of Arg1
and Arg2, were low at baseline (Figs. 2 and 3), suggesting
that inhibition of arginase would have little effect on
healthy mice. However, we observed that administration
of norNOHA to healthy control mice modestly attenu-
ated HPV. It is possible that, even in the presence of low
baseline levels of arginase, norNOHA was able to in-
crease the level of L-arginine available to NOS (pri-
marily NOS3), resulting in more NO production,
which exerted pulmonary vasodilating effects that op-
pose HPV (Fig. 6b).
To the best of our knowledge, this is the first study
that showed that NOS2 is required for the ability of
endotoxin to induce Arg1 in the lung. Although detailed
signaling mechanism of NOS2-dependent Arg1 induction
was not explored in the current study, protein S-nitrosyla-
tion induced by NOS2-derived NO has been shown to
regulate transcription. For example, NOS2-dependent
S-nitrosylation inhibits deacetylase sirtuin1 (SIRT1) dur-
ing inflammation [11]. Inhibition of SIRT1 in turn acti-
vates signal transducer and activator of transcription 3
Fig. 5 Hypoxic pulmonary vasoconstriction and arterial oxygenation.
Panel A: Mice were challenged with saline (control) or endotoxin
(LPS). After 21 h, the animals were treated with normal saline (NS) or
the arginase inhibitor norNOHA (20 mg/kg or 40 mg/kg). HPV was
assessed as the left pulmonary vascular resistance (LPVR) in response
to left mainstem bronchus occlusion (LMBO). Treatment with the
arginase inhibitor norNOHA (40mg/kg) restored HPV in endotoxemic
mice. Panel B: Arterial blood gas tensions were measured during LMBO
at the end of the experiments. The restoration of HPV was associated
with improved arterial oxygenation (PaO2) in endotoxemic mice
treated with 40mg/kg norNOHA compared to saline treatment. N = 7
per group; data presented as mean ± SD; * P < 0.05 vs. control group
treated with NS, § P < 0.05 vs. LPS group treated with normal saline,
† LPS group treated with 20mg/kg norNOHA
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(STAT3) by increasing acetylation and phosphorylation of
STAT3 [12]. Therefore, NOS2-dependent S-nitrosylation
may activate STAT3-dependent transcription. Because
STAT6/STAT3 are known promoters of Arg1 expres-
sion, it is conceivable that endotoxin-induced NOS2
upregulated Arg1 expression via STAT3 activation
[13].
In this study, endotoxin challenge increased Arg1
mRNA and protein expression in homogenized lung tis-
sue. The immunohistochemistry revealed a marked in-
crease of Arg1 expression in the small pulmonary
arteries, bronchial epithelium, and connective tissues.
HPV is intrinsic to the pulmonary arterial smooth
muscle cells. However, HPV is also modified by extrinsic
factors derived from neighboring cell types such as
vascular endothelial cells and macrophages [1]. Arg1
is typically expressed in liver, red blood cells, and
macrophages, but can be expressed in vascular endo-
thelial cells and smooth muscle cells [14, 15]. It is
conceivable that Arg1 induction in multiple cell types
modulates HPV during endotoxemia.
By reducing blood flow to poorly ventilated re-
gions, HPV optimizes the match between ventilation
and perfusion in the hypoxic regions of the lung and
improves arterial oxygenation [1]. In this study, we
observed that endotoxin challenge impaired HPV
and decreased arterial oxygenation. In contrast, ad-
ministration of arginase inhibitor during endotoxe-
mia restored HPV and improved arterial oxygenation
to the levels comparable to healthy control mice
treated with normal saline. These results indicate
Arg1 as a potential new therapeutic target for endotoxin-
induced ventilation perfusion mismatch associated with
systemic hypoxemia.
Twenty-two hours after endotoxin challenge, HPV was
impaired in mice treated with normal saline, whereas
administration of 40 mg/kg norNOHA restored HPV.
Because inhibition of arginase can theoretically make
more L-arginine available for NOS to produce NO, the
observed protective effect of norNOHA on HPV is
counterintuitive. However, the L-arginine levels, and
therefore the substrate availability for NOS to produce
NO, differs under healthy and pro-inflammatory condi-
tions. Sepsis and endotoxemia reduce L-arginine levels
[16, 17]. It has also been shown that NOS2-dependent
S-nitrosylation activates Arg1 by stabilizing Arg1 trimer
thus shifting more L-arginine to Arg1-dependent signaling
[18]. In any case, decreased L-arginine availability can re-
sult in uncoupling of NOS (predominantly NOS2 under
pro-inflammatory condition), with decreased production
of NO and increased production of reactive oxygen
species (ROS) (Fig. 6c) [19]. Increased oxidative stress
and decreased anti-oxidant capacity have been re-
ported in LPS-induced lung injury [19, 20]. We previ-
ously showed that treatment with ROS-scavengers
attenuates endotoxin-induced impairment of HPV [7].
It has been reported that arginase inhibition preserves
NOS coupling thereby reduces ROS production and
vascular endothelial dysfunction in aging rats [21]. It
is conceivable that norNOHA attenuated NOS-uncoupling,
ROS production, and redox imbalance to preserve HPV in
endotoxemic mice (Fig. 6d).
An alternative explanation for the observed restoration
of HPV in endotoxemic mice treated with norNOHA is
that the inhibitor may decrease the level of arginase
downstream products, such as ornithine and polyamines.
The polyamines putrescine, spermidine, and spermine
are small polycationic molecules that rectify ion channel
conductance [22]. Altered ion conductance in pulmon-
ary artery smooth muscle cells modulates HPV [1]. Poly-
amine catabolism has also been shown to increase
oxidative stress which may promote redox imbalance
Table 1 Arterial blood gas analyses
Control LPS
NS norNOHA
(40mg/kg)
NS norNOHA
(20mg/kg)
norNOHA
(40mg/kg)
PaO2
(mmHg)
267±38 200±38* 178±13* 204±44* 234±25§
PaCO2
(mmHg)
30.9±5.1 30.9±3.5 34.0±5.0 36.7±8.4 30.7±4.8
pHa
(mmHg)
7.31±0.10 7.37±0.05 7.13±0.07*‡ 7.07±0.08*‡ 7.11±0.04*‡
BE
(mmol/l)
-9.0±5.1 -6.4±2.0* -17.5±1.6*‡ -18.4±4.6*‡ -19.7±2.5*‡
Hb
(g/dl)
13.0±1.0 13.0±1.1 11.8±1.1 11.7±1.4 11.8±1.3
Mice were challenged with saline (control) or endotoxin (LPS). After 21 h, animals received treatment with normal saline (NS) or the arginase inhibitor Nω-hydroxy
nor-Arginine (norNOHA). Blood gas analyses were performed during occlusion of the left mainstem bronchus. N = 7 per group
PaO2 arterial oxygen tension, PaCO2 arterial carbon dioxide tension, pHa arterial pH, BE base excess, Hb hemoglobin, mmHg millimeters of mercury, mmol / l
milimoles per liter, g/dl gram per deciliter
Data are presented as mean ± SD. * P < 0.05 vs. control NS, § P < 0.05 vs. LPS NS, ‡ P < 0.05 vs. control norNOHA
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[23]. The potential role of arginine metabolites in certain
cell populations (such as vascular smooth muscle cells)
in the regulation of HPV remains to be defined.
It is possible that other factors, in addition to NOS2
and Arg1, contribute to the impairment of HPV. For
example, endothelial protein C receptor (also known
as activated protein C receptor) was the second most
up-regulated gene in the lungs of endotoxemic
wild-type mice after Arg1 (Additional file 1). Richard
and colleagues reported that administration of acti-
vated protein C worsened oxygenation, presumably
due to increased ventilation-perfusion mismatching,
in a porcine model of acute lung injury [24]. The
potential role of the endothelial protein C receptor
in regulating HPV during endotoxemia warrants fur-
ther studies.
A potential limitation of this investigation is the
small number of lungs that were used in the micro-
array analyses. However, the transcriptional profiling
was designed as a pilot study to identify candidate
genes. Additional qPCRs and immunoblots were per-
formed to confirm that endotoxin induced Arg1 gene
expression in wild-type, but not NOS2−/− mice. A sec-
ond limitation concerns the immunohistochemistry.
After endotoxin challenge, Arg1 positive immuno-
staining was found in bronchial epithelium, small
Fig. 6 Hypothetical roles of arginase and arginase inhibition on HPV. a Arginase and nitric oxide synthase (NOS) compete for the common
substrate L-arginine. b In healthy control mice, the arginase inhibitor norNOHA may shift L-arginine to NOS thereby increasing the level
of NO that in turn attenuates HPV. c Endotoxemia increases expression of NOS2 and Arg1. NOS2-dependent S-nitrosylation may promote
Arg1 expression and activity. Increased Arg1 may decrease L-arginine concentration locally. Low local arginine levels might promote NOS2
uncoupling and reactive oxygen species (ROS) production. Increased NO levels and redox imbalance impairs HPV. Upregulated Arg1 also
potentially increases downstream products including L-ornithine and polyamines, which may also impair HPV. d Inhibition of arginase by
norNOHA restores HPV by preventing NOS2 uncoupling and ROS production by shifting more L-arginine to NOS2 and decreasing polyamines
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pulmonary arteries, and the connective tissue. How-
ever, no double staining was performed leaving the
specific cell type uncertain. Further studies are needed
to identify which cell types in lung tissue are respon-
sible for increased arginase activity.
Conclusions
In summary, transcriptional profiling identified Arg1
as a factor that might be required for endotoxin to
inhibit HPV in wild-type mice. The arginase inhibi-
tor norNOHA, at a dose of 40 mg/kg, acutely re-
stored HPV in endotoxemic mice. These results
identify arginase as a novel molecular target to im-
prove pulmonary ventilation-perfusion matching dur-
ing endotoxemia.
Additional files
Additional file 1: Up-regulated genes in the lungs of endotoxemic
wild-type, but not NOS2-deficient mice. We previously showed that HPV
is preserved in endotoxemic NOS2-deficient (NOS2−/−) mice. [2]. The ob-
jective of this study was to identify gene products that may contribute to
endotoxin-induced impairment of HPV in wild-type mice. Transcription
profiling was
performed on homogenized lung tissue from wild-type mice 22 h after
LPS administration (N = 3) and compared to the profile produced by the
lungs of wild-type mice challenged with saline LPS (N = 4). Transcription
profiling was also performed on homogenized lung tissue from NOS2−/−
mice 22 h after LPS administration (N = 3) and was compared to the pro-
file produced by the lungs of NOS2−/− mice challenged with saline (N =
1). The microarray assessed the expression of 22,690 genes. A subset of
59 genes (shown in this table) was increased greater than three-fold in
wild-type mice challenged with
endotoxin, but was not enhanced three-fold in the lungs of NOS2−/−
mice challenged with endotoxin. The microarray results indicated that
Arg1 was the most highly expressed gene in endotoxemic wild-type
mice, and that Arg1
expression was not increased in the lungs of endotoxemic NOS2−/− mice.
(DOCX 1424 kb)
Additional file 2: Down-regulated genes in the lungs of endotoxemic
wild-type mice, but not endotoxemic NOS2-deficient mice. Expression of
72 genes was decreased to 0.3-fold or less by endotoxin in wild-type
mice, but was not decreased by endotoxin in NOS2−/− mice. (DOCX 2071
kb)
Additional file 3: Up-regulated genes in the lungs of endotoxemic
NOS2−/− mice, but not in endotoxemic wild-type mice. Expression of 155
genes was increased more than three-fold by endotoxin in NOS2−/− mice,
but was not similarly increased by endotoxin in wild-type mice. (DOCX 3039
kb)
Additional file 4: Down-regulated genes in the lungs of endotoxemic
NOS2−/− mice, but not in endotoxemic wild-type mice. Ninety-three
genes were decreased to 0.3-fold or less by endotoxin in NOS2−/− mice,
but were not decreased by endotoxin in wild-type mice. (DOCX 2346 kb)
Abbreviations
Arg1: Arginase 1; Arg2: Arginase 2; BE: Base excess; Hb: Hemoglobin;
HPV: Hypoxic pulmonary vasoconstriction; HR: Heart rate; LMBO: Left main
bronchus occlusion; LPS: Lipopolysaccharide; LPVR: Left pulmonary vascular
resistance; NO: Nitric oxide; norNOHA: Nω-hydroxy-nor-L-arginine; NOS2: Nitric
oxide synthase 2; NOS2−/−: NOS2-deficiency; NOS3: Nitric oxide synthase 3;
NS: Normal saline; ODC: L-ornithine decarboxylase; PaCO2: Arterial carbon
dioxide tension; PaO2: Arterial oxygen tension; PAP: Pulmonary arterial pressure;
pHa: Arterial pH; Procr: Endothelial protein C receptor (activated protein C
receptor); QLPA: Left pulmonary arterial blood flow; ROS: Reactive oxygen
species; SAP: Systemic arterial pressure; SIRT1: Sirtuin1; STAT3: Signal transducer
and activator of transcription 3
Acknowledgements
We thank Dr. Zapol for valuable comments and support. Histology and
immunohistology services were provided by the Tissue Bank for Inflammatory
Diseases Heidelberg (GEZEH), which was funded by the DFG (SFB 938 TP Z2 to
F.L.). We acknowledge financial support by Deutsche Forschungsgemeinschaft
within the funding program Open Access Publishing, by the Baden-
Württemberg Ministry of Science, Research and the Arts and by Ruprecht-Karls-
Universität Heidelberg.
Funding
This study was supported by NIH grant GM79360 (FI).
Availability of data and materials
The microarray data including information requested by the Microarray Gene
Expression Data society can be accessed in the microarray database at NCBI
Gene Expression Omnibus (GEO) using the following link: https://www.ncbi.
nlm.nih.gov/geo/query/acc.cgi?acc=GSE130936. Data sets of microarray
analysis (MOE430A Annotations, CSV format, Release 36, 4/13/16) are
obtainable at http://www.affymetrix.com/support/technical/
annotationfilesmain.affx).
Authors’ contributions
BP and CJB carried out the experiments, analyzed the data, and wrote the
manuscript with support from DBB and FI. GS contributed to sample
preparation. DS performed the microarray analysis. FL carried out experiments.
KDB and FI devised the project. FI and DBB interpreted the data and revised the
manuscript. FI approved the final version of the manuscript to be published. All
authors read and approved the final manuscript.
Ethics approval
All animal experiments were approved by the Subcommittee in Research
Animal Care of the Massachusetts General Hospital.
Consent for publication
Not applicable
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Anesthesia Center for Critical Care Research, Department of Anesthesia,
Critical Care and Pain Medicine, Massachusetts General Hospital and Harvard
Medical School, 55 Fruit Street, Boston, MA 02114, USA. 2Department of
Anesthesiology and Intensive Care Medicine, Campus Virchow-Klinikum,
Charité Universitätsmedizin, Berlin, Germany. 3Department of Anesthesiology,
Ruprecht Karls University, Heidelberg, Germany. 4Institute of Pathology,
Ruprecht Karls University, Heidelberg, Germany. 5Division of Rheumatology,
Allergy and Immunology, Department of Medicine, Massachusetts General
Hospital and Harvard Medical School, Boston, USA.
Received: 17 December 2018 Accepted: 30 April 2019
References
1. Sylvester JT, Shimoda LA, Aaronson PI, Ward JP. Hypoxic pulmonary
vasoconstriction. Physiol Rev. 2012;92:367–520.
2. Ullrich R, Bloch KD, Ichinose F, Steudel W, Zapol WM. Hypoxic pulmonary
blood flow redistribution and arterial oxygenation in endotoxin-challenged
NOS2-deficient mice. J Clin Invest. 1999;104:1421–9.
3. Ichinose F, Zapol WM, Sapirstein A, Ullrich R, Tager AM, Coggins K, Jones R,
Bloch KD. Attenuation of hypoxic pulmonary vasoconstriction by endotoxemia
requires 5-lipoxygenase in mice. Circ Res. 2001;88:832–8.
4. Ichinose F, Hataishi R, Wu JC, Kawai N, Rodrigues AC, Mallari C, Post JM,
Parkinson JF, Picard MH, Bloch KD, Zapol WM. A selective inducible NOS
Petersen et al. Respiratory Research          (2019) 20:109 Page 10 of 11
dimerization inhibitor prevents systemic, cardiac, and pulmonary
hemodynamic dysfunction in endotoxemic mice. Am J Physiol Heart
Circ Physiol. 2003;285:H2524–30.
5. Petersen B, Austen KF, Bloch KD, Hotta Y, Ichinose F, Kanaoka Y, Zapol WM.
Cysteinyl leukotrienes impair hypoxic pulmonary vasoconstriction in endotoxemic
mice. Anesthesiology. 2011;115:804–11.
6. Marshall BE, Hanson CW, Frasch F, Marshall C. Role of hypoxic pulmonary
vasoconstriction in pulmonary gas exchange and blood flow distribution.
Pathophysiology Intensive Care Med. 1994;20:379–89.
7. Baboolal HA, Ichinose F, Ullrich R, Kawai N, Bloch KD, Zapol WM. Reactive oxygen
species scavengers attenuate endotoxin-induced impairment of hypoxic
pulmonary vasoconstriction in mice. Anesthesiology. 2002;97:1227–33.
8. Steinbicker AU, Liu H, Jiramongkolchai K, Malhotra R, Choe EY, Busch CJ, Graveline
AR, Kao SM, Nagasaka Y, Ichinose F, Buys ES, Brouckaert P, Zapol WM, Bloch KD.
Nitric oxide regulates pulmonary vascular smooth muscle cell expression of the
inducible cAMP early repressor gene. Nitric Oxide. 2011;30:294–302.
9. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK. Limma powers
differential expression analyses for RNA-sequencing and microarray studies.
Nucleic Acids Res. 2015;43:e47.
10. Morris SM Jr. Recent advances in arginine metabolism: roles and regulation
of the arginases. Br J Pharmacol. 2009;157:922–30.
11. Shinozaki S, Chang K, Sakai M, Shimizu N, Yamada M, Tanaka T, Nakazawa H,
Ichinose F, Yamada Y, Ishigami A, Ito H, Ouchi Y, Starr ME, Saito H, Shimokado K,
Stamler JS, Kaneki M. Inflammatory stimuli induce inhibitory S-nitrosylation of the
deacetylase SIRT1 to increase acetylation and activation of p53 and
p65. Sci Signal. 2014;7:ra106.
12. Nie Y, Erion DM, Yuan Z, Dietrich M, Shulman GI, Horvath TL, Gao Q. STAT3
inhibition of gluconeogenesis is downregulated by SirT1. Nat Cell Biol. 2009;
11:492–500.
13. KE S, Shandilya H, Kepka-Lenhart D, Poljakovic M, Ghosh A, Morris SM Jr.
Shaping the murine macrophage phenotype: IL-4 and cyclic AMP
synergistically activate the arginase I promoter. J Immunol. 2013;191:
2290–8.
14. Caldwell RW, Rodriguez PC, Toque HA, Narayanan SP, Caldwell RB. Arginase:
A Multifaceted Enzyme Important in Health and Disease. Physiol Rev. 2018;
98:641–65.
15. Hochstedler CM, Leidinger MR, Maher-Sturm MT, Gibson-Corley KN,
Meyerholz DK. Immunohistochemical detection of arginase-I expression
in formalin-fixed lung and other tissues. J Histotechnol. 2013;36:128–34.
16. Luiking YC, Hallemeesch MM, Vissers YL, Lamers WH, Deutz NE. In vivo
whole body and organ arginine metabolism during endotoxemia (sepsis) is
dependent on mouse strain and gender. J Nutr. 2004;134:2768S–74S
discussion 2796S-2797S.
17. Luiking YC, Ten Have GA, Wolfe RR, Deutz NE. Arginine de novo and nitric
oxide production in disease states. Am J Physiol Endocrinol Metab. 2012;
303(10):E1177–89.
18. Santhanam L, Lim HK, Lim HK, Miriel V, Brown T, Patel M, Balanson S, Ryoo S,
Anderson M, Irani K, Khanday F, Di Costanzo L, Nyhan D, Hare JM, Christianson
DW, Rivers R, Shoukas A, Berkowitz DE. Inducible NO synthase dependent S-
nitrosylation and activation of arginase1 contribute to age-related endothelial
dysfunction. Circ Res. 2007;101:692–702.
19. Gross CM, Rafikov R, Kumar S, Aggarwal S, Ham PB 3rd, Meadows ML, Cherian-
Shaw M, Kangath A, Sridhar S, Lucas R, Black SM. Endothelial nitric oxide synthase
deficient mice are protected from lipopolysaccharide induced acute lung
injury. PLoS One. 2015;10:e0119918.
20. Zhang HX, Liu SJ, Tang XL, Duan GL, Ni X, Zhu XY, Liu YJ, Wang CN. H2S
attenuates LPS-induced acute lung injury by reducing oxidative/Nitrative stress and
inflammation. Cell Physiol Biochem. 2016;40:1603–12.
21. Kim JH, Bugaj LJ, Oh YJ, Bivalacqua TJ, Ryoo S, Soucy KG, Santhanam L,
Webb A, Camara A, Sikka G, Nyhan D, Shoukas AA, Ilies M, Christianson DW,
Champion HC, Berkowitz DE. Arginase inhibition restores NOS coupling and
reverses endothelial dysfunction and vascular stiffness in old rats. J Appl
Physiol. 2009;107:1249–57.
22. Weiger TM, Hermann A. Cell proliferation, potassium channels, polyamines
and their interactions: a mini review. Amino Acids. 2014;46:681–8.
23. Stewart TM, Dunston TT, Woster PM, Casero RA. Polyamine catabolism and
oxidative damage. J Biol Chem. 2018;293:18736–45.
24. Richard JC, Bregeon F, Leray V, Le Bars D, Costes N, Tourvieille C, Lavenne F,
Devouassoux-Shisheboran M, Gimenez G, Guerin C. Effect of activated protein C
on pulmonary blood flow and cytokine production in experimental acute lung
injury. Intensive Care Med. 2007;33:2199–206.
Petersen et al. Respiratory Research          (2019) 20:109 Page 11 of 11
